A prospective study to compare the efficacy of noradrenaline verses terlipressin in hepatorenal syndrome in patients with advanced cirrhosis

Srishti Nayyar*, Ranjeet Kaur, Gurinder Mohan, Manish Chandey

INTRODUCTION

Cirrhosis is characterized by fibrosis and formation of nodules in the liver parenchyma as a complication to chronic insult, leading on to alteration of normal lobular organization of the liver. Traditionally, it has been classified as compensated and decompensated cirrhosis and progression from compensated to decompensated state happens by account of development of ‘Portal hypertension’. The occurrence of complications, namely variceal haemorrhage, ascites, spontaneous bacterial peritonitis, encephalopathy, hepatorenal syndrome or hepatopulmonary syndrome mark the onset of decompensated cirrhosis. The Hepatorenal syndrome (HRS) is a form of functional renal failure without any histological renal pathology that occurs in about 10% of patients with advanced cirrhosis and is associated with very poor prognosis. The term ‘Hepatorenal syndrome’ was first coined by surgeons in the 1930’s to describe renal failure occurring after biliary surgery or hepatic trauma in patients with previously normal renal function.

There are marked disturbances in the arterial renal circulation in patients with HRS and currently, the
Current diagnostic criteria are based on an exclusion-based approach using serum creatinine as a biomarker. According to the latest 2015 position paper, HRS is diagnosed using the following revised criteria: (1) cirrhosis with ascites; (2) increase in serum creatinine >0.3 mg/dl or >50% or >1.5 times over baseline in 48 hours; (3) absence of shock; (4) absence of hypovolemia as defined by no sustained improvement of renal function following 2 days of diuretic withdrawal (if on diuretics) and volume expansion with albumin at a dose of 1 g/kg/day (maximum 100 g/day); (5) absence of current or recent treatment with diuretics; and (6) absence of renal parenchymal disease as indicated by proteinuria >500 mg/day, microscopic hematuria (>50 RBC/high power field) and/or abnormal renal ultrasonography.

There are 4 types of HRS: (a) HRS type 1 (Acute HRS)- progressive impairment in renal function and significant decrease in creatinine clearance within 1-2 weeks of presentation (doubling of initial serum creatinine to >2.5 mg/dl). There is multiorgan failure. Carries 80% mortality at 2 weeks; (b) HRS type 2 (chronic HRS)- reduction in GFR with rise in serum creatinine and refractory ascites, but is fairly stable, occurs gradually over weeks to months with serum creatinine of 1.5-2.5 mg/dl, usually associated with refractory ascites and has better prognosis than type 1; (c) HRS type 3: cirrhosis with types 1 or 2 HRS superimposed on chronic kidney disease or acute renal injury with median survival of 6 months; and (d) HRS type 4: fulminant liver failure with HRS.

METHODS
This hospital based, longitudinal comparative interventional study was carried out in Department of Medicine, Sri guru ram das charitable hospital attached to Sri Guru Ram Das Institute of Medical Sciences and Research, Sri Amritsar, Punjab during a period of March 2019 to August 2020. Cirrhosis was diagnosed based on clinical, biochemical, radiological means. HRS was diagnosed according to the standard criteria proposed by International Club of Ascitis: (1) cirrhosis with ascites; (2) increase in serum creatinine >0.3 mg/dl or >50% or >1.5 times over baseline in 48 hours; (3) absence of shock; (4) absence of hypovolemia as defined by no sustained improvement of renal function following 2 days of diuretic withdrawal (if on diuretics) and volume expansion with albumin at a dose of 1 g/kg/day (maximum 100 g/day); (5) absence of current or recent treatment with diuretics; and (6) absence of renal parenchymal disease as indicated by proteinuria >500 mg/day, microscopic hematuria (>50 RBC/high power field) and/or abnormal renal ultrasonography.

Inclusion criteria
Patients with following criteria were included- (1) patients presenting with advanced cirrhosis with HRS and age
between 18-80 years; and (2) patients who give consent for the study protocol by signing the informed consent.

**Exclusion criteria**

Patients with following criteria were excluded- (1) improvement in renal function after central blood volume expansion; (2) evidence of chronic kidney disease; (3) presence of severe sepsis, pancreatitis, or shock; (4) history of use of nephrotoxic drugs; (5) history of coronary artery disease, cardiomyopathy, ventricular arrhythmia, or obliterator arterial disease of the limbs; (6) patients undergoing renal replacement therapy; (7) patients with obstructive uropathy. Randomisation was carried out by dividing 60 patients into 2 groups (group A and group B) using stratified randomisation technique to receive treatment for 1 week.

Randomisation of participants into adrenaline and terlipressin groups was done using sequentially numbered, opaque sealed envelopes (SNOSE). Group A received continuous infusion of noradrenaline at an initial dose of 0.5 mg/hr via an automated infusion pump (maximum up to 3 mg/hr) aimed to achieve an increase in urine output of more than 100 ml in one day or increase in Mean arterial pressure (MAP) of up to 10 mm of Hg after being diagnosed with HRS. Group B received terlipressin at doses of 1 mg intravenously every 6 h until the serum creatinine level reduced to less than 1.5 mg/dl on two measurements 48 h apart. If even after 3 days the serum creatinine did not decline by at least 30% from baseline, the dose of terlipressin was increased to 2 mg every 6 h, with a cumulative maximum dose up to 12 mg/day. Patients in both the groups received daily IV albumin 20 g/day until the end of the study period. All patients had an indwelling urinary catheter for accurate measurement of urine output. Following formula was used for calculation of MAP:

\[
MAP = DP + \frac{1}{3} (SBP - DBP) \text{ or } MAP \\
= DBP + \frac{1}{3} (PP)
\]

Where DP is diastolic blood pressure, SP is systolic blood pressure and PP is pulse pressure. Primary investigations done at the initiation of therapy were complete blood count, Prothrombin time index, liver function tests, renal function tests and serum electrolytes, Ascitic fluid studies, viral markers, ultrasonography, cultures.

Improvment in renal function was monitored in terms of increments in daily urine output and renal function tests were repeated every third day to see the improvement in serum creatinine. Response to treatment was defined as:

**Complete response**

Increase in serum creatinine to a value of 1.5 mg/dl or lower during the treatment.

**Partial response**

Decrease of 50% or greater in the serum creatinine level compared with the baseline value to a final value higher than 1.5 mg/dl.

**No response**

Decrease of <50% as compared with baseline value or an increase in serum creatinine compared with the baseline value. The primary end point of the study was- complete response (i.e.; reversal of HRS); the secondary end points- completion of 1 week of therapy or death. Data has been expressed as mean with standard deviation (SD) for quantitative variables. The results have been analysed at baseline and at the end of therapy. Comparisons between groups have been performed using Student’s t-test and ANOVA test for quantitative variables and Chi square test for nominal/qualitative data. The baseline characteristics of all the patients have been compared in each treatment arm. A value of p<0.05 has been taken as significant.

**RESULTS**

As shown in Figure 1, 30 patients were allocated to each study group and received noradrenaline infusion+albumin (20 g/day) in group A and terlipressin boluses+albumin in group B according to aforementioned protocol until primary or secondary end points were achieved. While no patients were lost to follow up and in no patient therapy was discontinued due to side effects of the drugs, 8 patients died in group receiving noradrenaline, 5 of which died because of massive upper GI bleed and 3 died from upper UGI bleed. So, in our final study, 22 patients have been assessed in group receiving noradrenaline and 29 patients have been assessed in group receiving terlipressin. Baseline variables of each group have been shown in Table 1.

96.5% of patients in the terlipressin group but mere 31.8% in the noradrenaline group, in our study, responded to treatment. The response was also classified as complete and partial response based on fall of creatinine levels (complete response: decrease in serum creatinine to a value of 1.5 mg/dl or lower during the treatment. Partial response: decrease of 50% or greater in the serum creatinine level compared with the baseline value to a final value higher than 1.5 mg/dl). 89.7% patients were complete responders and 6.9% were partial responders in terlipressin group in our study, while 31.8% of patients in noradrenaline group showed only partial response in our study. Majority of patients (68.2%) in noradrenaline group showed no response (decrease of <50% as compared with baseline value or an increase in serum creatinine compared with the baseline value) while only 3.4% of patients in terlipressin group failed to respond to the treatment (Figure 2 and 3). In present study, noradrenaline group showed change in serum creatinine from 3.91±1.58 mg/dl to 3.07±1.68 mg/dl, p=0.007 and terlipressin group from 3.21±1.24 mg/dl to 1.36±0.87 mg/dl, p<0.001 (Table 2).
Our study showed a significant increase in MAP in both study groups (noradrenaline group- from 76.93±6.18 mmHg to 89.49±6.93 mmHg, p<0.001; terlipressin group from 75.54±5.51 mmHg to 89.92±5.07 mmHg, p<0.001) (Table 4). Both drugs increased the urine output in our study but change was more significant with terlipressin (noradrenaline group- from 493.41±240.42 ml/day to 781.27±342.57 ml/day, p=0.006; terlipressin group from 485.69±212.79 ml/day to 1346.21±544.64 ml/day, p<0.001) (Table 3).

### Table 1: Baseline characteristics in two study groups.

| Characteristics     | Noradrenaline group (N=22) | Terlipressin group (N=29) | P value |
|---------------------|----------------------------|---------------------------|---------|
| Age (years)         | 54.64±15.60                | 53.45±13.01               | 0.143   |
| Males (%)           | 72.7                       | 82.8                      | 0.388   |
| Etiology (%)        |                            |                           |         |
| Alcohol             | 63.6                       | 72.4                      | 0.503   |
| Hepatitis C         | 27.3                       | 44.8                      | 0.199   |
| Others              | 18.2                       | 3.4                       | 0.080   |
| Mean child pugh score | 10.86±1.16                | 11.34±1.34                | 0.256   |
| Mean MELD score     | 29.45±6.26                 | 28.79±6.31                | 0.175   |
| Mean serum bilirubin (mg/dl) | 4.81±5.33            | 5.20±5.56                 | 0.297   |
| Mean serum albumin (g/dl) | 2.15±0.62            | 2.12±0.50                 | 0.041   |
| Mean serum sodium (mmol/l) | 133.76±6.98        | 134.17±6.05               | 0.201   |
| Mean serum creatinine (mg/dl) | 3.91±1.58            | 3.21±1.24                 | 0.635   |
| MAP (mm of Hg)      | 76.93±6.18                 | 75.54±5.51                | 0.045   |

Note: Data was expressed as mean±standard deviation, MELD: Model for end stage liver disease, MAP: Mean arterial pressure.

### Table 2: Mean change in serum creatinine (in mg/dl) in both study groups.

| Groups   | Serum creatinine | P value |
|----------|------------------|---------|
|          | Baseline         | End of therapy | Change |
|Noradrenaline | 3.91±1.58        | 3.07±1.68 | 0.84±0.28 | 0.007* |
|Terlipressin | 3.21±0.24        | 1.36±0.87 | 1.85±0.21 | <0.001* |

### Table 3: Mean change in urine output (in ml/day) in both study groups.

| Groups   | Urine output | P value |
|----------|--------------|---------|
|          | Baseline     | End of therapy | Change |
|Noradrenaline | 493.41±240.42 | 781.27±342.57 | 287.86±93.99 | 0.006 |
|Terlipressin | 485.69±212.79 | 1346.21±544.64 | 860.52±102.18 | <0.001 |

### Table 4: Mean change in mean arterial pressure (map in mmHg) in both study groups.

| Groups   | Map | P value |
|----------|-----|---------|
|          | Baseline     | End of therapy | Change |
|Noradrenaline | 76.93±6.18 | 89.49±6.93 | 12.55±1.32 | <0.001 |
|Terlipressin | 75.54±5.51 | 89.92±5.07 | 14.37±0.95 | <0.001 |

**Figure 1: Showing flow of participants in both groups.**
DISCUSSION

The present longitudinal comparative interventional study was conducted in the setting of a tertiary care center with the aim of assessing the efficacy of noradrenaline versus terlipressin in HRS in patients with advanced cirrhosis using serum creatinine as the index biomarker for assessing the response to treatment. Our study is double blinded and is one of the few studies that directly compares the efficacy of these 2 drugs in treatment of patients with advanced cirrhosis with HRS. Most of the earlier studies were unblinded.14,16,18 Our study was meant to assess the response in both HRS type 1 and type 2 like the pilot study but all the patients enrolled in our study were of HRS type 1 by a probability of chance.14 Most of the studies done till now also compared the 2 drugs’ response in HRS type 1.16,17,19,20 The comparison of response rates has been shown in Table 5.

Table 5: Comparison of response rates of hrs with noradrenaline and terlipressin in various studies.

| Study            | N   | HRS type                  | Noradrenaline (%) | Terlipressin (%) |
|------------------|-----|---------------------------|-------------------|-----------------|
| Alessandria et al14 | 22  | HRS type 1 and HRS type 2 | 70                | 83              |
| Badawy et al15    | 51  | HRS type 1                | 40                | 46.15           |
| Ghosh et al16     | 46  | HRS type 2                | 73                | 73.9            |
| Sharma et al17    | 40  | HRS type 1                | 55                | 55              |
| Singh et al18     | 46  | HRS type 1                | 43.4              | 39.1            |
| Goyal et al19     | 41  | HRS type 1                | 47.6              | 45              |
| Indrabi et al20   | 60  | HRS type 1                | 53                | 57              |
| Present study     | 51  | HRS type 1                | 31.8              | 96.5            |
Our study demographics were similar to previous studies. Mean age of patients was 54.04 years in our study with male (78.4%) to female (21.6%) ratio of 3.6:1, just like in all other studies where mean age of patients lied in the age group of 40-60 years with male sex predominance. This could be due to the fact that males have higher incidence of developing cirrhosis following decades of alcohol consumption, which was found to be the most common etiology of cirrhosis in our patients similar to all previous studies. 68.6% of total patients analyzed (N=51) had history of chronic alcohol consumption, all of them being males in our study as no female patients gave any positive history. This could be due to the taboo surrounding alcohol consumption by females in India which is hence culturally prohibited in female population of India. The second common cause of cirrhosis in our study was hepatitis C virus (HCV) reactivity (37.3%) seen in both males and females. This was because HCV poses a significant health problem in the state of Punjab, India owing to the higher prevalence of risk factors like unsafe medical practices (including unsafe injections and dental procedures) and intravenous drug usage

In our study, since both drugs showed unequal responses, no further analysis was possible for ascertaining other factors as having prognostic significance in predicting the outcome of treatment in both study groups between responders and non-responders. Although a cost-effectiveness analysis was not the main aim of this study, the cost of noradrenaline was found to be lower than terlipressin. However, terlipressin has some advantage over noradrenaline as it is given as an intravenous bolus through a peripheral vein, while noradrenaline is given intravenously as a continuous infusion preferably via a central venous catheter, usually in the setting of intensive care unit that nullifies the cost benefit gained from lesser cost of this drug. Mapping survival of patients post therapy was not the aim of this study.

Our study has few limitations. First is the small sample size. This problem has been faced by most of the previous investigators also, as it is difficult to get a large number of patients with this morbid condition at a single centre. Most of the previously published studies could also enrol about 50 patients only. Secondly, plasma renin, urine sodium excretion and aldosterone levels were not measured in our study.

CONCLUSION

Our study suggests that noradrenaline might not be an attractive and equally efficacious alternative to use of terlipressin in HRS, as suggested by previous studies. Larger multi-centric clinical trials comparing noradrenaline with terlipressin in the treatment of HRS are required to draw firm conclusions on this subject.

Funding: No funding sources

Ethical approval: The study was approved by the Institutional Ethics Committee

REFERENCES

1. Patrick S, Vijay H. Overview of Cirrhosis. Sleisenger and Fortran’s Gastrointestinal and Liver Disease. 11th ed. Canada: Elsevier; 2020: 1164-1171.
2. Ng CK, Chan MH, Tai MH, Lam CW. Hepatorenal syndrome. Clin Biochem Rev. 2007;28(1):11-7.
3. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol. 2014;60(1):197-209.
4. Albillos A, Hera A, González M, Moya JL, Calleja JL, Monserrat J, et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37(1):208-17.
5. Oettl K, Gruenberger R, Spindelboeck W, Stueger HP, Dorn L, Stadlbauer V, et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J Hepatol. 2013;59(5):978-83.
6. Jalan R, Schultz K, Mookerjee RP, Sen S, Cheshire L, Hodges S, et al. Alterations in the functional capacity of albumin in patients with decompensated cirrhosis is associated with increased mortality. Hepatology. 2009;50(2):555-64.
7. Xiong J, Pu L, Xiong H, Xiang P, Zhang M, Liu J, Li A. Evaluation of the criteria of hepatorenal syndrome type of acute kidney injury in patients with cirrhosis admitted to ICU. Scand J Gastroenterol. 2018;53(12):1590-6.
8. Jalan R, Saibla F, Pavesi M, Amoros A, Moreau R, Giniès P, et al. Development and validation of a prognostic score to predict mortality in patients with acute-on-chronic liver failure. J Hepatol. 2014;61(5):1038-47.
9. Rodriguez E, Henrique PG, Solà E, Elia C, Barreto R, Pose E, et al. Treatment of type 2 hepatorenal syndrome in patients awaiting transplantation: Effects on kidney function and transplantation outcomes. Liver Transpl. 2015;21(11):1347-54.
10. Panteris V, Karamanolis DG. The puzzle of somatostatin: action, receptors, analogues and therapy. Hepatogastroenterology. 2005;52(66):1771-81.
11. Schmidt LE, Larsen H. Vasoconstrictor therapy for hepatorenal syndrome in liver cirrhosis. Curr Pharm Des. 2006;12(35):4637-47.
12. Cavallin M, Kamath PS, Merli M, Fasolato S, Toniutto P, Salerno F, et al. Terlipressin plus albumin versus midodrine and octreotide plus albumin in the treatment of hepatorenal syndrome: A randomized trial. Hepatology. 2015;62(2):567-74.
13. Sharma P, Kumar A, Shrama BC, Sarin SK. An open label, pilot, randomized controlled trial of noradrenaline versus terlipressin in the treatment of...
type 1 hepatorenal syndrome and predictors of response. Am J Gastroenterol. 2008;103(7):1689-97.

14. Alessandria C, Ottobrelli A, Venon W, Todros L, Cerenzia MT, Martini S, et al. Noradrenalin vs terlipressin in patients with hepatorenal syndrome: a prospective, randomized, unblinded, pilot study. J Hepatol. 2007;47(4):499-505.

15. Kamath PS, Wiesner RH, Malinchoc M, Kremers W, Therneau TM, Kosberg CL, et al. A model to predict survival in patients with end-stage liver disease. Hepatology. 2001;33(2):464-70.

16. Singh V, Ghosh S, Singh B, Kumar P, Sharma N, Bhalla A, et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome: a randomized study. J Hepatol. 2012;56(6):1293-8.

17. Goyal O, Sidhu SS, Sehgal N, Puri S. Noradrenaline is as Effective as Terlipressin in Hepatorenal Syndrome Type 1: A Prospective, Randomized Trial. J Assoc Physicians India. 2016;64(9):30-5.

18. Indrabi RA, Javid G, Zargar SA, Khan BA, Yattoo GN, Shah SH, et al. Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome: a randomized prospective study. Clin Experim Hepatol. 2013;3(1):97.

19. Angeli P, Volpin R, Gerunda G, Craighero R, Roner P, Merenda R, et al. Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide. Hepatology. 1999;29(6):1690-7.

20. Wong F, Pantea L, Sniderman K. Midodrine, octreotide, albumin, and TIPS in selected patients with cirrhosis and type 1 hepatorenal syndrome. Hepatology. 2004;40(1):55-64.

21. Badawy SS, Meckawy NM, Ahmed A. Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide, midodrine, and albumin (a prospective randomized comparative study). Egyptian J Cardiothoracic Anesthesia. 2013;7(1):13.

22. Ghosh S, Choudhary NS, Sharma AK, Singh B, Kumar P, Agarwal R, et al. Noradrenaline vs terlipressin in the treatment of type 2 hepatorenal syndrome: a randomized pilot study. Liver Int. 2013;33(8):1187-93.

23. Magder SA. The highs and lows of blood pressure: toward meaningful clinical targets in patients with shock. Critical Care Med. 2014;42(5):1241-51.

Cite this article as: Nayyar S, Kaur R, Mohan G, Chandey M. A prospective study to compare the efficacy of noradrenaline versus terlipressin in hepatorenal syndrome in patients with advanced cirrhosis. Int J Adv Med 2021;8:1312-8.